title: Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kaul
authors.forename: Ann F
authors.initials: AF
authors.lastname: Bolger
authors.forename: David
authors.initials: D
authors.lastname: Herrington
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
authors.forename: Robert H
authors.initials: RH
authors.lastname: Eckel
mesh_terms: D000572:American Heart Association; D002309:Cardiology; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D017202:Myocardial Ischemia / Q000139:chemically induced; D000077205:Pioglitazone; D000077154:Rosiglitazone; D012955:Societies, Medical; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone